2D-DIGE as a strategy to identify serum biomarkers in Mexican patients with Type-2 diabetes with different body mass index

Gómez-Cardona, Erik E; Hernández-Domínguez, Eric E.; Velarde‐Salcedo, Aída Jimena; Pacheco, Alberto-Barrera; Diaz-Gois, Agustín; León‐Rodríguez, Antonio De; Rosa, Ana

doi:10.1038/srep46536

Cited by 13 publications

(11 citation statements)

References 56 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is evidence to support the association between APOH and lipid metabolism, inflammation, thrombosis, autoimmune disease, and atherosclerosis. 46 , 47 Here, expression levels of APOH were upregulated in DM1 patients. The analysis of plasma levels of APOH from people with DM2 showed that patients with hypertriglyceridemia had significantly higher APOH values.…”

Section: Discussionmentioning

confidence: 74%

Proteomic analysis to identify candidate biomarkers associated with type 1 diabetes

Oliveira

Lima-Neto

Tilburg

et al. 2018

DMSO

View full text Add to dashboard Cite

PurposeType 1 diabetes mellitus (DM1) is one of the most common chronic diseases observed during childhood. The incidence of DM1 is increasing worldwide, and there is currently no way to prevent or delay the onset or to cure the disease. Most diseases, including diabetes, stem from abnormalities in the functioning of proteins, and some studies have reported the expression of protein variation to be involved in the development of DM1. Thus, the aim of this study was to investigate the differential expression of serum proteins in patients with DM1.Materials and methodsSerum of patients with DM1 (n=30) and healthy controls (n=30) was collected. A proteomic approach was used with depletion of albumin and immunoglobulin G chromatography on serum samples followed by data-independent, label-free mass spectrometric analysis.ResultsA total of eight serum proteins were identified as being differentially expressed and involved in the immune system, lipid metabolism, and pathways of coagulation. DM1 was associated with the upregulation of six proteins: alpha-2-macroglobulin, apolipoprotein A-II, β2 glycoprotein I, Ig alpha-2 chain C region, alpha-1-microglobulin, and prothrombin. A total of two proteins were downregulated, including pregnancy zone protein and complement C4.ConclusionTo the best of our knowledge, these findings show differential expression of proteins revealing new proteins that may be involved in the development and progression of diabetes.

show abstract

Section: Discussionmentioning

confidence: 74%

Proteomic analysis to identify candidate biomarkers associated with type 1 diabetes

Oliveira

Lima-Neto

Tilburg

et al. 2018

DMSO

View full text Add to dashboard Cite

show abstract

“…However, 2‐DE is laborious, time‐consuming, and poorly reproducible in technical replicates. The later introduction of fluorescent Cy dyes (Cy2, Cy3, and Cy5), known as 2D‐DIGE (Two‐Dimensional Differential Gel Electrophoresis), can greatly improve protein quantitation precision by running the pooled Cy‐dye labeled protein ample on the same 2D gel . However, the later‐staining of gels by other visible dyes in 2D‐DIGE is necessary to excise the protein spots for MS analysis, but the gel re‐staining may bring concern about the accuracy of protein spot location.…”

Section: Pancreatic Cancer (Pc)mentioning

confidence: 99%

“…51 In the biomarker discovery stage, gel-based and gel-free Differential Gel Electrophoresis), can greatly improve protein quantitation precision by running the pooled Cy-dye labeled protein ample on the same 2D gel. 52 However, the later-staining of gels by other visible dyes in 2D-DIGE is necessary to excise the protein spots for MS analysis, but the gel re-staining may bring concern about the accuracy of protein spot location.…”

Section: Ms-based Proteomic Approaches For Protein Biomarker Discovmentioning

confidence: 99%

Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry

Chang

Chen

2020

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

Rationale Chronic pancreatitis (CP) is a pancreatic disease with poor prognosis and pancreatic cancer (PC) is one of the most lethal types of cancer that is symptomless in the early stage. Because the clinical and image findings of CP can overlap that of pancreatic cancer (PC) which leads to confusion in the diagnosis and treatment of PC, discovery/verification/validation of more accurate protein biomarkers to diagnose CP and PC is in urgent need. Methods The PubMed, Web of Science, and Google Scholar were searched using the keywords: ‘biomarker’, ‘marker’, ‘chronic pancreatitis’, “pancreatic cancer” or “proteomics” for highly related researches. We focused on the articles published after the year 2005 in this review. Results We introduce the background to CP and PC and summarize the diagnosis of CP and PC, analytically validated protein biomarkers, and proteomic approaches for discovery/verification/validation. The potential use of mass spectrometry (MS) in clinical diagnosis is also discussed. Conclusions Continuously improving sensitivity of MS can provide deeper proteome for new marker discovery and high reliability for protein marker verification, validation, and clinical diagnosis. The analytically validated protein markers could be considered as targeted protein biomarkers for developing a MS platform in the clinical validation process or clinical diagnosis of CP and PC.

show abstract

“…On the other hand, protein markers have high sensitivity and specificity for T2D because they reflect the progression of the disease systemically and dynamically ( 13 ). Furthermore, proteins are tightly regulated by cellular stimulation; whereas genes are not ( 12 ). Thus, protein markers are practical and have potential for diabetic diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Identification of Novel Biomarkers for Pre-diabetic Diagnosis Using a Combinational Approach

et al. 2021

View full text Add to dashboard Cite

Reliable protein markers for pre-diabetes in humans are not clinically available. In order to identify novel and reliable protein markers for pre-diabetes in humans, healthy volunteers and patients diagnosed with pre-diabetes and stroke were recruited for blood collection. Blood samples were collected from healthy and pre-diabetic subjects 12 h after fasting. BMI was calculated from body weight and height. Fasting blood glucose (FBG), glycated hemoglobin (HbA1C), triglyceride (TG), total cholesterol, high-density lipoprotein, low-density lipoprotein (LDL), insulin and albumin were assayed by automated clinical laboratory methods. We used a quantitative proteomics approach to identify 1074 proteins from the sera of pre-diabetic and healthy subjects. Among them, 500 proteins were then selected using Mascot analysis scores. Further, 70 out of 500 proteins were selected via volcano plot analysis according to their statistical significance and average relative protein ratio. Eventually, 7 serum proteins were singled out as candidate markers for pre-diabetes due to their diabetic relevance and statistical significance. Immunoblotting data demonstrated that laminin subunit alpha 2 (LAMA2), mixed-lineage leukemia 4 (MLL4), and plexin domain containing 2 (PLXDC2) were expressed in pre-diabetic patients but not healthy volunteers. Receiver operating characteristic curve analysis indicated that the combination of the three proteins has greater diagnostic efficacy than any individual protein. Thus, LAMA2, MLL4 and PLXDC2 are novel and reliable serum protein markers for pre-diabetic diagnosis in humans.

show abstract

2D-DIGE as a strategy to identify serum biomarkers in Mexican patients with Type-2 diabetes with different body mass index

Cited by 13 publications

References 56 publications

Proteomic analysis to identify candidate biomarkers associated with type 1 diabetes

Proteomic analysis to identify candidate biomarkers associated with type 1 diabetes

Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry

Identification of Novel Biomarkers for Pre-diabetic Diagnosis Using a Combinational Approach

Contact Info

Product

Resources

About